AI-assisted (epi-)genetic screening platforms for toxicology and efficacy studies
CompanyToxGenSolutions B.V., Maastricht, Netherlands
The company ToxGenSolutions specializes in identifying drug targets and developing new drugs. The company's goal is to detect severe diseases (such as neurodegenerative diseases, cancer, (auto-)immune deficiencies) at an early stage and stop them in their tracks. Based on (epi)genetic data sets, computer tools identify potential drug candidates. For toxicity and efficacy evaluation, human spheroids are exposed to the active ingredient to be tested and subjected to high-throughput screening. The AI-based methods accelerate previous complex and time-consuming testing procedures. They also open up the possibility of developing personalized medicines. In addition to processes for developing and testing the safety and efficacy of new active ingredients, the company also develops various methodological tools to optimize early diagnostics. Currently, ToxGenSolutions is working to validate a diagnostic tool that will enable preclinical diagnosis of Alzheimer's disease with a focus on differences between men and women.
ToxGenSolutions
erwin.roggen@toxgensolutions.eu
Added on: 11-22-2023
[1] https://toxgensolutions.eu/
